Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

This Pharma Stock Is Still a ‘Strong Buy’ Despite Trump’s Plans to Lower Drug Prices

Despite Trump’s executive order to cut drug prices, Eli Lilly’s stock surged, showing strong resilience and impressive gains amidst regulatory concerns.

Are Wall Street Analysts Bullish on Eli Lilly Stock?

Are Wall Street Analysts Bullish on Eli Lilly Stock?

Despite lagging behind the broader market over the past year, Eli Lilly continues to enjoy a highly bullish outlook from Wall Street analysts, who remain confident in the company’s long-term growth potential.

Wegovy maker Novo Nordisk cuts profit forecast as US prescriptions tail off

Wegovy maker Novo Nordisk cuts profit forecast as US prescriptions tail off

Slowdown will deepen concerns Denmark’s biggest company is losing market share to US rival Eli Lilly

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Novo Nordisk cuts guidance as weight-loss drug market competition grows

Novo Nordisk shares jumped following stronger-than-expected first-quarter earnings, despite the company lowering its growth outlook for 2025 amid intensifying competition in the weight-loss drug markets.

Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?

Shares of Eli Lilly just got walloped. So, is the company still the name to own in GLP-1s, or are the tables turning on this pharma giant?

This Left-for-Dead Penny Stock Just Got a Major Boost. Should You Buy It Now?

This penny stock has received a big boost after reports of bankruptcy began to circulate.

World Health Organization makes U-turn on weight loss jabs

The decision is a significant shift in the WHO’s approach to drugs like Wegovy

The Independent UK

inkl

Read news from The Economist, FT, and more,
with one subscription

Trump hints at tariff reprieve for pharma companies that bring operations back to US

Trump hints at tariff reprieve for pharma companies that bring operations back to US

He suggests drugmakers would get ‘a lot of time’ to repatriate manufacturing before facing levies

The Guardian - UK

Stocks Soar Before the Open on Upbeat Microsoft and Meta Results, More Big Tech Earnings on Tap

Stocks Soar Before the Open on Upbeat Microsoft and Meta Results, More Big Tech Earnings on Tap

June S&P 500 E-Mini futures (ESM25) are up +1.18%, and June Nasdaq 100 E-Mini futures (NQM25) are up +1.68% this morning as forecast-beating quarterly results from Microsoft and Meta boosted sentiment.

Viagra and Mounjaro panic-buying could explain Ireland's 200% export surge to U.S.

Viagra and Mounjaro panic-buying could explain Ireland's 200% export surge to U.S.

U.S. multinational activity propelled the Irish economy to 3.2% growth in the first quarter, as Trump fears come into focus.

Ozempic maker spending more than $3m to lobby fat cats in Washington as weight-loss drugs faces regulatory decisions

Ozempic maker spending more than $3m to lobby fat cats in Washington as weight-loss drugs faces regulatory decisions

Novo Nordisk has hired multiple lobbying firms to persuade lawmakers to take a harder line on companies producing versions of the drugs that have not been approved by the FDA

The Independent UK

2 ‘Strong Buy’ Stocks to Buy on Plans to Increase American Manufacturing

2 ‘Strong Buy’ Stocks to Buy on Plans to Increase American Manufacturing

Two checkered names from diverse industries are looking to bolster their manufacturing capabilities in the U.S. Here's how they stack up as investment ideas.

Trade war with China to hit US healthcare

Trade war with China to hit US healthcare

Without a carve-out for tariff exceptions for pharmaceuticals, prices will skyrocket for US patients, experts warn.

Eli Lilly Nails Oral GLP-1 Trial—Here’s What It Means for LLY

Eli Lilly Nails Oral GLP-1 Trial—Here’s What It Means for LLY

Take a deep dive into Eli Lilly's latest clinical GLP-1 results that sent shares soaring. The company has a big opportunity to serve needle-phobic patients.

Get all your
news in one place.

100's of premium titles.
One news app.

Eli Lilly's Quarterly Earnings Preview: What You Need to Know

Eli Lilly is scheduled to report its first-quarter results next month, and analysts expect a significant double-digit earnings growth.

The Guardian - UK

Swiss drugmaker Roche to invest $50bn in US in effort to dodge Trump tariffs

Company says it will create 12,000 jobs in manufacturing and R&D over next five years

Goldman Sachs Just Upgraded This Blue-Chip Stock. Should You Buy It Now?

With a strong pipeline, this pharmaceutical powerhouse is positioning itself as a dominant force in the future of medicine.

The Independent UK

Daily weight-loss pill may work as well as Ozempic and could replace injections

Patients in a trial taking orforglipron lost an average of 7.2kg over nine months

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

New daily weight-loss pill shows success at clinical trial

Orforglipron also reduced blood sugar levels in participants with type 2 diabetes

Experimental daily pill found to aid weight loss in what could be alternative to jabs like Ozempic

Other weight loss drugs must be injected, meaning the new pill from pharmaceutical giant Eli Lilly could become patients’ top choice if it is approved.

Analysts Love These 2 Stocks to Buy for Q2

Investors could snag these two stocks as BofA flags the companies as well-positioned winners in an uncertain quarter.

Hims’ Weight Loss Expansion: Real Growth or Just Hype?

Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite?

Experimental Drug Shows Promise In Eliminating Hard-To-Treat Deadly Cholesterol

A single dose of lepodisiran dramatically lowered dangerous lipoprotein(a) levels for up to a year, offering new hope for heart disease treatment.

Novo Nordisk shares post the biggest monthly decline since 2002

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several disappointing trial results. However, analysts remain optimistic about the shares, forecasting a potential price upside of up to 60% over the next 12 months.

The Times of India

Who should avoid taking viral drug Mounjaro? Expert explains

Eli Lilly's recent launch of Mounjaro (tirzepatide) in India has sparked significant interest especially among those looking for weight loss and diabetes control.

1 … 13 14 15 16

People

190,072 stories

Robert F. Kennedy Jr

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

the White House

Amazon.com Inc.

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Executive Order

Places

374,746 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play